Schnitzer Steel Industries Inc

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.  The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.  Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.  Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Schnitzer Steel Reports Q3 Loss, Focuses on Strategic Growth

Schnitzer Steel is navigating a challenging market landscape with strategic initiatives aimed at improving margins and capitalizing on favorable demand trends. The company is focused on cost control, productivity improvements, and strategic investments to position itself for recovery and growth in a transitioning industry.

Schnitzer Steel Industries Inc doubles EBITDA in Q4 2024

Schnitzer Steel Industries Inc delivered a robust performance in Q4 2024, driven by increased sales volumes and cost-saving initiatives amidst challenging market conditions.
The company showcased strengths in managing operational efficiency, capitalizing on favorable market trends, and maintaining financial flexibility with manageable debt levels.
While facing challenges such as market headwinds and high capital expenditures, Schnitzer Steel has opportunities to further enhance operational efficiency, capitalize on market trends, and drive revenue growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Radius Recycling, Inc. engages in the recycling of ferrous and nonferrous scrap metal and manufacture of finished steel products. The company was founded by Sam Schnitzer in 1906 and is headquartered in Portland, OR.

Urges Stockholders to Vote “FOR” Radius' Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE Proxy Card

Radius Files Definitive Proxy and Mails Letter to Stockholders

Radius Health (RDUS) will pause all work on the abaloparatide transdermal system based on regulatory clarity, timeline and costs.

Radius (RDUS) to Stop Work on Abaloparatide Transdermal System

Shares of Radius Health Inc. RDUS, -1.90% were down 1.1% in premarket trading on Thursday, the day after the company said it will stop development of its abaloparatide transdermal system, which is a patch used to dispense Radius' osteoporosis drug. The decision has been expected by investors since Radius said in December that a Phase 3 trial did not meet its primary endpoint.

Radius to stop development of patch for osteoporosis drug

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided an update on the abaloparatide transdermal system (abalo-TDS) development program.

Radius Health Update on Abaloparatide Transdermal System

Radius (RDUS) and partner Menarini announce data from a late-stage study on breast cancer drug.

Radius (RDUS), Menarini Post Positive Data on Breast Cancer Drug

The Menarini Group and Radius Health Inc's (NASDAQ: RDUS) data from the phase 3 EMERALD trial evaluating elacestrant for ER+/HER2- advanced or metastatic breast cancer were published in the Journal of Clinical Oncology. The company says that elacestrant is the first oral.

Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer

Further Expands Board's Expertise and Gender Diversity

Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors

Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patients PFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% vs.

Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology

Radius Health, Inc. (NASDAQ:RDUS ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Ethan Holdaway - Head of Investor Relations Kelly Martin - President and CEO Mark Conley - Chief Financial Officer Bob Valentine - Strategic Business Officer Chhaya Shah - Senior Vice President and Chief Business Officer Liz Messersmith - Neuroscience Group Conference Call Participants Corinne Jenkins - Goldman Sachs Annabel Samimy - Stifel Mary Kate - Bank of America Na Sun - JPMorgan Eun Yang - Jefferies Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear.

Radius Health, Inc. (RDUS) CEO Kelly Martin on Q1 2022 Results - Earnings Call Transcript

Radius (RDUS) posts a y/y wider Q1 loss and misses revenue estimates.

Radius (RDUS) Q1 Loss Wider Than Expected, Revenues Decline

Radius Health (RDUS) delivered earnings and revenue surprises of -85.71% and 16.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Radius Health (RDUS) Reports Q1 Loss, Lags Revenue Estimates

BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the first quarter ended March 31, 2022. The Company also provided a general business update.

Radius Health, Inc. First Quarter 2022 Results

Radius Health (RDUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Radius Health (RDUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

BOSTON, April 25, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that it will release its first quarter 2022 financial results on Thursday, May 5, 2022. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the results and provide a business update.

Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022

BOSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS), today announced appointments to new roles on its executive leadership team, effective immediately.

Radius Health Announces Leadership Appointments

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided an update on business development and intellectual property progress in its Bone Health franchise.

Radius Health Provides Business Update on Bone Health

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that Kelly Martin, CEO, has accepted an invitation to participate in a virtual fireside chat hosted by Mohit Bansal, Managing Director of Equity Research at Wells Fargo. The event will take place on Friday, March 11, 2022 at 11:00am ET.

Wells Fargo Equity Research to Host Fireside Chat with Radius CEO

The consensus price target hints at a 90.9% upside potential for Radius Health (RDUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Radius Health (RDUS) Could Surge 91%: Read This Before Placing a Bet

Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing.

Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates

Radius Health, Inc.'s (RDUS) CEO Kelly Martin on Q4 2021 Results - Earnings Call Transcript

Radius Health (RDUS) delivered earnings and revenue surprises of 5.71% and 3.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Radius Health (RDUS) Reports Q4 Loss, Tops Revenue Estimates

BOSTON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided key business and financial objectives for 2022.

Radius Health, Inc. Fourth Quarter & Full Year 2021 Results

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Radius Health (RDUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BOSTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the results and provide a company update.

Radius Health to Release Fourth Quarter and Full Year 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, February 24, 2022

BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), has completed an adjustment of its business.

News for Schnitzer Steel Industries Inc Stock (RDUS)